# US 2003/0211165 A1 · Microspheres for active embolization

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0211165 A1
- Document ID: US20030211165A1
- Status: Published application
- Kind: A1
- Application number: 10/220,982
- Filed: 2002-12-12
- Published: 2003-11-13
- Earliest claimed: 2002-12-12
- Assignees: Biosphere Medical, Inc.
- Inventors: Jean-Marie Vogel; Egisto Boschetti
- Web page: https://patentgrep.com/patent/US20030211165A1

## CPC

- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61L 2430/36: for embolization or occlusion, e.g. vaso-occlusive compositions or devices
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y10T 428/2982: Particulate matter [e.g., sphere, flake, etc.]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) for use in embolization drug therapy. The present invention further relates to methods of embolization gene therapy, particularly for the treatment of angiogenic and non-angiogenic-dependent diseases, using the injectable compositions.

## Claims

### Claim 1

A microsphere suitable for active embolization comprising a biocompatible, cross-linked and substantially hydrophilic polymer and one or more active components comprising a drug, a vaccine, or any combination thereof.

### Claim 2 (depends on 1)

The microsphere of claim 1, wherein the microsphere comprises one or more elastomers.

### Claim 3 (depends on 2)

The microsphere of claim 2, wherein the elastomers are selected from the group consisting of acrylic polymers, acrylamide polymers, vinyl alcohol polymers, acrylate polymers, polysaccharides, silicones, and mixtures thereof.

### Claim 4 (depends on 2)

The microsphere of claim 2, wherein the diameter of the microsphere ranges from about 10 μm to about 2000 μm.

### Claim 5 (depends on 4)

The microsphere of claim 4, wherein the diameter of the microsphere ranges from about 50 μm to about 300 μm.

### Claim 6 (depends on 1)

The microsphere of claim 1, wherein the microsphere is swellable.

### Claim 7 (depends on 6)

The microsphere of claim 6, wherein the microsphere comprises polymers selected from the group consisting of sodium acrylate polymer, acrylamide polymer, acrylamide derivative polymer or copolymer, sodium acrylate and vinyl alcohol copolymer, vinyl acetate and acrylic acid ester copolymer, vinyl acetate and methyl maleate copolymer, isobutylene-maleic anhydride crosslinked copolymer, starch-acrylonitrile graft copolymer, crosslinked sodium polyacrylate polymer, and crosslinked polyethylene oxide.

### Claim 8 (depends on 6)

The microsphere of claim 6, wherein the diameter of the microsphere ranges from about 10 μm to about 400 μm before swelling.

### Claim 9 (depends on 8)

The microsphere of claim 8, wherein the diameter of the microsphere ranges from about 10 μm to about 200 μm before swelling.

### Claim 10 (depends on 6)

The microsphere of claim 6, where the diameter of the microsphere ranges from about 10 μm to about 2000 μm after swelling.

### Claim 11 (depends on 1)

The microsphere of claim 1, wherein the drug is selected from the group consisting of anti-tumor, anti-angiogenesis, anti-fungal, antiviral, anti-inflammatory drug, anti-bacterial drug, and anti-histamine drug.

### Claim 12 (depends on 1)

The microsphere of claim 1, wherein the vaccine is selected from the group consisting of pneumococcus vaccine, poliomyelitis vaccine, anthrax vaccine, tuberculosis (BCG) vaccine, hepatitis A vaccine, cholera vaccine, meningococcus A, C, Y vaccines, W135 vaccine, plague vaccine, rabies (human diploid) vaccine, yellow fever vaccine, Japanese encephalitis vaccine, typhoid (phenol and heat-killed) vaccine, hepatitis B vaccine, diptheria vaccine, tetanus vaccine, pertussis vaccine, H. influenzae type b vaccine, polio vaccine, measles vaccine, mumps vaccine, rubella vaccine, varicella vaccine, streptococcus pneumoniae Ty (live mutant bacteria) vaccine, Vi (Vi capsular polysaccharide) vaccine, DT (toxoid) vaccine, Td (toxoid) vaccine, aP (inactive bacterial antigen/accelular (DtaP)) vaccine, Hib (bacterial polysaccharide-protein conjugate) vaccine, hepatitis B virus (inactive serum derived viral antigen/recombinant antigen) vaccine, influenza vaccine, rotavirus vaccine, respiratory syncytial virus (RSV) vaccine, human astrovirus vaccine, rotavirus vaccine, human influenza A and B virus vaccine, hepatitis A virus vaccine, live attenuated parainfluenza virus type 3 vaccine, enterovirus vaccines, retrovirus vaccines, and picornavirus vaccines.

### Claim 13 (depends on 1)

The microsphere of claim 1, further comprising an imaging agent or contrast media selected from the group consisting of fluorescent markers derivatives, chemical dyes, and magnetic resonance imaging agents.

### Claim 14 (depends on 1)

The microsphere of claim 1, wherein the polymer comprises from about 0.5% to about 20%, by molecular weight, of crosslinkers.

### Claim 15 (depends on 1)

An injectable composition comprising the microsphere of claim 1 and a biocompatible carrier.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the composition comprises the microsphere in an amount from about 10% to about 90% by weight and the biocompatible carrier in an amount from about 10% to about 30% by weight.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the composition comprises the microspheres in an amount from about 10% to about 50% by weight and the biocompatible carrier in an amount from about 50% to about 90% by weight.

### Claim 18 (depends on 15)

The composition of claim 15, wherein the composition is a suspension of said microspheres in said biocompatible carrier.

### Claim 19 (depends on 18)

The composition of claim 18, wherein the biocompatible polymer is in an emulsion.

### Claim 20 (depends on 18)

The composition of claim 18, wherein the biocompatible polymer is in an organic or non-aqueous solution.

### Claim 21 (depends on 18)

The composition of claim 18, wherein the biocompatible polymer is in an aqueous based solution, a hydro-organic solution, or mixtures thereof.

### Claim 22 (depends on 18)

The composition of claim 18, wherein the biocompatible carrier comprises salts composed of cations selected from the group consisting of sodium, potassium, calcium, magnesium, iron, zinc, and ammonium in an amount of from about 0.01 M to about 5 M.

### Claim 23 (depends on 22)

The composition of claim 22, wherein the salt is supplied in form of a contrast agent.

### Claim 24 (depends on 18)

The composition of claim 18, wherein the contrast agent is monomeric (acrylamido-3-propionamido)-3-triiodo-2,4,6-benzoic acid.

### Claim 25 (depends on 15)

The composition of claim 15, where the composition is injectable through a needle of about 18 gauge or smaller.

### Claim 26

A method for active embolization in a mammal comprising administering to a mammal in need of treatment a microsphere comprising a biocompatible, cross-linked and substantially hydrophilic polymer and one or more drugs, vaccines, or combinations thereof.

### Claim 27 (depends on 26)

The method of claim 26, wherein the microsphere comprises one or more elastomers.

### Claim 28 (depends on 27)

The method of claim 27, wherein the elastomers are selected from the group consisting of acrylic polymers, acrylamide polymers, vinyl alcohol polymers, acrylate polymers, polysaccharides, silicones, and mixtures thereof.

### Claim 29 (depends on 27)

The method of claim 27, wherein diameter of the microsphere ranges from about 10 μm to about 2000 μm.

### Claim 30 (depends on 29)

The method of claim 29, wherein the diameter of the microsphere ranges from about 50 μm to about 300 μm.

### Claim 31 (depends on 26)

The method of claim 26, wherein the microsphere is swellable.

### Claim 32 (depends on 31)

The method of claim 31, wherein the microsphere comprises ionic polysaccharides and ionic synthetic polymers.

### Claim 33 (depends on 32)

The method of claim 32, wherein the ionic polysaccharides are selected from the group consisting of carboxymethyldextran, dextran sulphate, and algenic acid.

### Claim 34 (depends on 32)

The method of claim 32, wherein the ionic synthetic polymers are selected from the group consisting of sodium acrylate polymer, acrylamide polymer, acrylamide derivative polymer or copolymer, sodium acrylate and vinyl alcohol copolymer, vinyl acetate and acrylic acid ester copolymer, vinyl acetate and methyl maleate copolymer, isobutylene-maleic anhydride crosslinked copolymer, starch-acrylonitrile graft copolymer, crosslinked sodium polyacrylate polymer, and crosslinked polyethylene oxide.

### Claim 35 (depends on 31)

The method of claim 31, wherein diameter of the microsphere ranges from about 10 μm to about 400 μm before swelling.

### Claim 36 (depends on 35)

The method of claim 35, wherein the diameter of the microsphere ranges from about 10 μm to about 200 μm before swelling.

### Claim 37 (depends on 31)

The method of claim 31, where diameter of the microsphere ranges from about 10 μm to about 2000 μm after swelling.

### Claim 38 (depends on 26)

The method of claim 26, wherein the therapeutically active drug is selected from the group consisting of anti-tumor, anti-angiogenesis, anti-fungal, antiviral, anti-inflammatory drug, anti-bacterial drug, and anti-histamine drug, anti-angiogenic factor, antineoplastic agents, hormones and steroids, vitamins, peptides and peptide analogs, enzymes, anti-allergenic agents, circulatory drugs, anti-tubercular agents, anti-viral agents, anti-anginal agents, anti-protozoan agents, anti-rheumatic agents, narcotics, cardiac glycoside agents, sedatives, local anesthetic agents, general anesthetic agents.

### Claim 39 (depends on 26)

The method of claim 26, wherein the vaccine is selected from the group consisting of pneumococcus vaccine, poliomyelitis vaccine, anthrax vaccine, tuberculosis (BCG) vaccine, hepatitis A vaccine, cholera vaccine, meningococcus A, C, Y vaccines, W135 vaccine, plague vaccine, rabies (human diploid) vaccine, yellow fever vaccine, Japanese encephalitis vaccine, typhoid (phenol and heat-killed) vaccine, hepatitis B vaccine, diptheria vaccine, tetanus vaccine, pertussis vaccine, H. influenzae type b vaccine, polio vaccine, measles vaccine, mumps vaccine, rubella vaccine, varicella vaccine, streptococcus pneumoniae Ty (live mutant bacteria) vaccine, Vi (Vi capsular polysaccharide) vaccine, DT (toxoid) vaccine, Td (toxoid) vaccine, aP (inactive bacterial antigen/accelular (DtaP)) vaccine, Hib (bacterial polysaccharide-protein conjugate) vaccine, hepatitis B virus (inactive serum derived viral antigen/recombinant antigen) vaccine, influenza vaccine, rotavirus vaccine, respiratory syncytial virus (RSV) vaccine, human astrovirus vaccine, rotavirus vaccine, human influenza A and B virus vaccine, hepatitis A virus vaccine, live attenuated parainfluenza virus type 3 vaccine, enterovirus vaccines, retrovirus vaccines, and picornavirus vaccines.

### Claim 40 (depends on 26)

The method of claim 26, wherein the microsphere further comprises a contrast media or a diagnostic agent selected from the group consisting of fluorescent markers derivatives, chemical dyes, and magnetic resonance imaging agents.

### Claim 41 (depends on 26)

The method of claim 26, wherein the polymer comprises from about 0.5% to about 20%, by molecular weight, of crosslinkers.

### Claim 42 (depends on 26)

The method of claim 26, wherein the administration comprises injecting into an area of said mammal in need of embolization.

### Claim 43 (depends on 1)

The microsphere of claim 1, wherein the anti-tumor drug is taxol, doxorubicin, tamoxifen, or a combination thereof.

### Claim 44

A method for active embolization in a mammal comprising administering to a mammal in need of treatment a microsphere comprising a biocompatible, cross-linked and substantially hydrophilic polymer and one or more drugs, vaccines, or combinations thereof, wherein said microsphere is delivered to the site of action by the use of targeting antibodies.
